Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

STOP-HAE: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of siRNA Targeting of Prekallikrein With ADX-324 in Participants With Hereditary Angioedema

NCT06960213 is registered in ClinicalTrials.gov with ADARx Pharmaceuticals, Inc. as lead sponsor.

NCT NCT06960213
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06960213 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
STOP-HAE: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of siRNA Targeting of Prekallikrein With ADX-324 in Participants With Hereditary Angioedema
Lead sponsor
ADARx Pharmaceuticals, Inc.
Phase
Phase 3
Overall status
Recruiting
Start date
August 28, 2025
Completion date
December 31, 2027
Enrollment
90 (estimated)
Sites
70

Conditions

As the registry lists them; a condition with its own page is linked.

hae, hereditary angioedema, hereditary angioedema - type 1, hereditary angioedema - type 2